Magnesium sulphate and other anticonvulsants for women with pre-eclampsia

Duley, Lelia; Gülmezoglu, A Metin; Henderson‐Smart, David J

doi:10.1002/14651858.cd000025

Cited by 267 publications

(274 citation statements)

References 36 publications

Supporting

Mentioning

228

Contrasting

Unclassified

Order By: Relevance

“…Magnesiumsulfat ist in etwa der Hälfte der Fälle von Eklampsie während der Geburt oder unmittelbar nach der Geburt bei Frauen mit Präeklampsie effektiv [774][775][776][777]. Verwenden Sie Magnesiumsulfat als Infusion zur Behandlung von Eklampsie [778][779][780][781].…”

Section: Präeklampsie Und Eklampsieunclassified

Kreislaufstillstand in besonderen Situationen

Truhlář

Deakin

Soar

et al. 2015

Notfall Rettungsmed

View full text Add to dashboard Cite

Section: Präeklampsie Und Eklampsieunclassified

Kreislaufstillstand in besonderen Situationen

Truhlář

Deakin

Soar

et al. 2015

Notfall Rettungsmed

View full text Add to dashboard Cite

“…14 A vasoconstrição arteriolar, em especial a cerebral, favorece a presença de múltiplas zonas de hemorragias promovidas pela ruptura do endotélio vascular, 7 causando vasoconstrição persistente, trombose, hipóxia cerebral, mais frequentes nos lobos occipitais. [20][21][22] Em geral, geram-se maiores números de áreas lesadas, de convulsões, e consequente piora do prognóstico materno. 1 O sulfato de magnésio tem reconhecida a sua superioridade em relação aos demais fármacos, conhecidos no controle e prevenção da recidiva de convulsões na eclâmpsia.…”

Section: Discussionunclassified

“…1 O sulfato de magnésio tem reconhecida a sua superioridade em relação aos demais fármacos, conhecidos no controle e prevenção da recidiva de convulsões na eclâmpsia. 22,23 A sua atuação seria por bloqueio neuronal dos canais de cálcio, indução da produção e liberação de prostaciclina, promovendo vasodilatação local, atenuando agonistas, reduzindo a isquemia cerebral. 23 Em nossa casuística notou-se, também, que as proporções de pacientes eclâmpticas foram declinando significantemente de 1995 a 2005.…”

Section: Discussionunclassified

Mortalidade materna por eclâmpsia

Novo

Gianini

2010

Rev. Bras. Saude Mater. Infant.

View full text Add to dashboard Cite

Objective: to assess the factors associated with maternal mortality resulting from eclampsia.Methods: a retrospective cohort study reviewing the medical records of deliveries carried out at the Sorocaba Hospital Compound (between January 1995 and December 2005 (0,90% para 0,37%; r= -0,746; p=0,008), mas mantendo a proporção de casos com sérias complicações (0,25% para 0,17%, r= -0,45; p=0,162). A proporção de óbitos foi maior entre pacientes não brancas (RR=9,10; IC95%=1,23; p=0,007) e menor entre as tratadas com sulfato de magnésio (RR=0,08; IC95%=0,35; p=0,001

show abstract

“…[6][7][8] The Magpie Trial showed that it is also effective for preventing the first eclamptic seizure, without substantive short-term harmful effects on either mother or baby. 9,10 The long-term impact of in utero exposure to magnesium sulphate is unclear. Case-control studies have suggested that maternal treatment shortly before birth may lower the risk of cerebral palsy in surviving very-lowbirthweight infants.…”

Section: Introductionmentioning

confidence: 99%

The Magpie Trial: A Randomised Trial Comparing Magnesium Sulphate with Placebo for Pre-Eclampsia. Outcome for Children at 18 Months

2007

Obstetric Anesthesia Digest

View full text Add to dashboard Cite

Objective To assess the long-term effects of in utero exposure to magnesium sulphate for children whose mothers had pre-eclampsia.Design Assessment at 18 months of age for children whose mothers were recruited to the Magpie Trial (recruitment 1998(recruitment -2001, which compared magnesium sulphate with placebo.Setting Follow-up of children born at 125 centres in 19 countries across five continents.Population A total of 6922 children were born to women randomised before delivery at follow-up centres. Of these, 2271 were not included for logistic reasons and 168 were excluded (101 at a centre where <20% were contacted, 40 whose death or disability was due to a problem at conception or embryogenesis and 27 whose parent/s opted out). Therefore, 4483 children were included in follow-up, of whom 3283 (73%) were contacted.Methods Assessment by questionnaire, with interview and neurodevelopmental testing of selected children.Main outcome measures Death or neurosensory disability at age of 18 months.Results Of those allocated magnesium sulphate, 245/1635 (15.0%) were dead or had neurosensory disability at 18 months compared with 233/1648 (14.1%) allocated placebo (relative risk [RR] 1.06, 95% CI 0.90-1.25), and of survivors, 19/1409 (1.3%) had neurosensory disability at 18 months compared with 27/1442 (1.9%) (RR 0.72, 95% CI 0.40-1.29). There were no substantial differences in causes of death or in the risk of individual impairments or disabilities.Conclusions The lower risk of eclampsia following prophylaxis with magnesium sulphate was not associated with a clear difference in the risk of death or disability for children at 18 months.

show abstract

Magnesium sulphate and other anticonvulsants for women with pre-eclampsia

Cited by 267 publications

References 36 publications

Kreislaufstillstand in besonderen Situationen

Kreislaufstillstand in besonderen Situationen

Mortalidade materna por eclâmpsia

The Magpie Trial: A Randomised Trial Comparing Magnesium Sulphate with Placebo for Pre-Eclampsia. Outcome for Children at 18 Months

Contact Info

Product

Resources

About